135 related articles for article (PubMed ID: 22045666)
1. PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications.
Yoshimoto M; Ludkovski O; DeGrace D; Williams JL; Evans A; Sircar K; Bismar TA; Nuin P; Squire JA
Genes Chromosomes Cancer; 2012 Feb; 51(2):149-60. PubMed ID: 22045666
[TBL] [Abstract][Full Text] [Related]
2. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.
Yoshimoto M; Cunha IW; Coudry RA; Fonseca FP; Torres CH; Soares FA; Squire JA
Br J Cancer; 2007 Sep; 97(5):678-85. PubMed ID: 17700571
[TBL] [Abstract][Full Text] [Related]
3. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer.
Sircar K; Yoshimoto M; Monzon FA; Koumakpayi IH; Katz RL; Khanna A; Alvarez K; Chen G; Darnel AD; Aprikian AG; Saad F; Bismar TA; Squire JA
J Pathol; 2009 Aug; 218(4):505-13. PubMed ID: 19402094
[TBL] [Abstract][Full Text] [Related]
4. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer.
Bismar TA; Yoshimoto M; Vollmer RT; Duan Q; Firszt M; Corcos J; Squire JA
BJU Int; 2011 Feb; 107(3):477-85. PubMed ID: 20590547
[TBL] [Abstract][Full Text] [Related]
5. Variable phenotypes associated with 10q23 microdeletions involving the PTEN and BMPR1A genes.
Menko FH; Kneepkens CM; de Leeuw N; Peeters EA; Van Maldergem L; Kamsteeg EJ; Davidson R; Rozendaal L; Lasham CA; Peeters-Scholte CM; Jansweijer MC; Hilhorst-Hofstee Y; Gille JJ; Heins YM; Nieuwint AW; Sistermans EA
Clin Genet; 2008 Aug; 74(2):145-54. PubMed ID: 18510548
[TBL] [Abstract][Full Text] [Related]
6. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.
Krohn A; Diedler T; Burkhardt L; Mayer PS; De Silva C; Meyer-Kornblum M; Kötschau D; Tennstedt P; Huang J; Gerhäuser C; Mader M; Kurtz S; Sirma H; Saad F; Steuber T; Graefen M; Plass C; Sauter G; Simon R; Minner S; Schlomm T
Am J Pathol; 2012 Aug; 181(2):401-12. PubMed ID: 22705054
[TBL] [Abstract][Full Text] [Related]
7. Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias.
Yoshimoto M; Cutz JC; Nuin PA; Joshua AM; Bayani J; Evans AJ; Zielenska M; Squire JA
Cancer Genet Cytogenet; 2006 Sep; 169(2):128-37. PubMed ID: 16938570
[TBL] [Abstract][Full Text] [Related]
8. Deletion of PTEN and BMPR1A on chromosome 10q23 is not always associated with juvenile polyposis of infancy.
Salviati L; Patricelli M; Guariso G; Sturniolo GC; Alaggio R; Bernardi F; Zuffardi O; Tenconi R
Am J Hum Genet; 2006 Sep; 79(3):593-6; author reply 596-7. PubMed ID: 16909400
[No Abstract] [Full Text] [Related]
9. Concurrent deletion of 16q23 and PTEN is an independent prognostic feature in prostate cancer.
Kluth M; Runte F; Barow P; Omari J; Abdelaziz ZM; Paustian L; Steurer S; Christina Tsourlakis M; Fisch M; Graefen M; Tennstedt P; Huland H; Michl U; Minner S; Sauter G; Simon R; Adam M; Schlomm T
Int J Cancer; 2015 Nov; 137(10):2354-63. PubMed ID: 26009879
[TBL] [Abstract][Full Text] [Related]
10. Deletion of 8p is an independent prognostic parameter in prostate cancer.
Kluth M; Amschler NN; Galal R; Möller-Koop C; Barrow P; Tsourlakis MC; Jacobsen F; Hinsch A; Wittmer C; Steurer S; Krech T; Büscheck F; Clauditz TS; Beyer B; Wilczak W; Graefen M; Huland H; Minner S; Schlomm T; Sauter G; Simon R
Oncotarget; 2017 Jan; 8(1):379-392. PubMed ID: 27880722
[TBL] [Abstract][Full Text] [Related]
11. Looking for the hidden mutation: Bannayan-Riley-Ruvalcaba syndrome caused by constitutional and mosaic 10q23 microdeletions involving PTEN and BMPR1A.
Golas MM; Auber B; Ripperger T; Pabst B; Schmidt G; Morlot M; Diebold U; Steinemann D; Schlegelberger B; Morlot S
Am J Med Genet A; 2019 Jul; 179(7):1383-1389. PubMed ID: 31062505
[TBL] [Abstract][Full Text] [Related]
12. Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas.
Wang SI; Parsons R; Ittmann M
Clin Cancer Res; 1998 Mar; 4(3):811-5. PubMed ID: 9533551
[TBL] [Abstract][Full Text] [Related]
13. Exploring prostate cancer genome reveals simultaneous losses of PTEN, FAS and PAPSS2 in patients with PSA recurrence after radical prostatectomy.
Ibeawuchi C; Schmidt H; Voss R; Titze U; Abbas M; Neumann J; Eltze E; Hoogland AM; Jenster G; Brandt B; Semjonow A
Int J Mol Sci; 2015 Feb; 16(2):3856-69. PubMed ID: 25679447
[TBL] [Abstract][Full Text] [Related]
14. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues.
Suzuki H; Freije D; Nusskern DR; Okami K; Cairns P; Sidransky D; Isaacs WB; Bova GS
Cancer Res; 1998 Jan; 58(2):204-9. PubMed ID: 9443392
[TBL] [Abstract][Full Text] [Related]
15. Loss of a small region around the PTEN locus is a major chromosome 10 alteration in prostate cancer xenografts and cell lines.
Hermans KG; van Alewijk DC; Veltman JA; van Weerden W; van Kessel AG; Trapman J
Genes Chromosomes Cancer; 2004 Mar; 39(3):171-84. PubMed ID: 14732919
[TBL] [Abstract][Full Text] [Related]
16. Analysis of PTEN and the 10q23 region in primary prostate carcinomas.
Feilotter HE; Nagai MA; Boag AH; Eng C; Mulligan LM
Oncogene; 1998 Apr; 16(13):1743-8. PubMed ID: 9582022
[TBL] [Abstract][Full Text] [Related]
17. Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer.
Hubbard GK; Mutton LN; Khalili M; McMullin RP; Hicks JL; Bianchi-Frias D; Horn LA; Kulac I; Moubarek MS; Nelson PS; Yegnasubramanian S; De Marzo AM; Bieberich CJ
Cancer Res; 2016 Jan; 76(2):283-92. PubMed ID: 26554830
[TBL] [Abstract][Full Text] [Related]
18. Large genomic deletions of SMAD4, BMPR1A and PTEN in juvenile polyposis.
van Hattem WA; Brosens LA; de Leng WW; Morsink FH; Lens S; Carvalho R; Giardiello FM; Offerhaus GJ
Gut; 2008 May; 57(5):623-7. PubMed ID: 18178612
[TBL] [Abstract][Full Text] [Related]
19. Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH.
Lotan TL; Wei W; Ludkovski O; Morais CL; Guedes LB; Jamaspishvili T; Lopez K; Hawley ST; Feng Z; Fazli L; Hurtado-Coll A; McKenney JK; Simko J; Carroll PR; Gleave M; Lin DW; Nelson PS; Thompson IM; True LD; Brooks JD; Lance R; Troyer D; Squire JA
Mod Pathol; 2016 Aug; 29(8):904-14. PubMed ID: 27174589
[TBL] [Abstract][Full Text] [Related]
20. The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion.
Verhagen PC; van Duijn PW; Hermans KG; Looijenga LH; van Gurp RJ; Stoop H; van der Kwast TH; Trapman J
J Pathol; 2006 Apr; 208(5):699-707. PubMed ID: 16402365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
